CD274 and hepatocellular carcinoma: The only data published involved patient-derived organoids cocultured with or without mesenchymal stem cells (MSCs), peripheral blood mononuclear cells (PBMCs), or CAFs from HCC patients receiving an anti-PD-L1 agent (atezolizumab); the expression of high levels of CD-38 was associated with resistance to treatment, while no differences in terms of response were associated with the expression of PD-L1.